Philipp Schommers
Overview
Explore the profile of Philipp Schommers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1855
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klingmuller A, Feldmann M, Rohr S, Helmhold L, Junker L, Scherer M, et al.
Infection
. 2025 Mar;
PMID: 40067569
Purpose: Tuberculosis (TB) remains a leading cause of morbidity and mortality, with 1.3 million deaths in 2022. Extrapulmonary tuberculosis (EPTB) accounts for approximately 20% of all TB cases. We assessed...
2.
Odidika S, Pirkl M, Lengauer T, Schommers P
Front Immunol
. 2025 Jan;
15():1443377.
PMID: 39835119
Antiretroviral therapy is the standard treatment for HIV, but it requires daily use and can cause side effects. Despite being available for decades, there are still 1.5 million new infections...
3.
Schmidt A, Casadei N, Brand F, Demidov G, Vojgani E, Abolhassani A, et al.
PLoS Pathog
. 2024 Dec;
20(12):e1012786.
PMID: 39715278
Courses of SARS-CoV-2 infections are highly variable, ranging from asymptomatic to lethal COVID-19. Though research has shown that host genetic factors contribute to this variability, cohort-based joint analyses of variants...
4.
Gruell H, Odidika S, Schommers P
Signal Transduct Target Ther
. 2024 Oct;
9(1):287.
PMID: 39402038
No abstract available.
5.
Hubel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, et al.
Hemasphere
. 2024 Sep;
8(9):e150.
PMID: 39233903
This EHA-ESMO Clinical Practice Guideline provides key recommendations for managing HIV-associated lymphomas.The guideline covers clinical, imaging and pathological diagnosis; staging and risk assessment; treatment and follow-up.The author group encompasses a...
6.
Lehmann C, Schommers P
Lancet Infect Dis
. 2024 Jul;
24(11):1178-1179.
PMID: 39038476
No abstract available.
7.
von Maltitz P, Wettstein L, Weil T, Schommers P, Klein F, Munch J
J Virol
. 2024 Mar;
98(4):e0119023.
PMID: 38501840
Topically applied microbicides may play a critical role in preventing sexual transmission of human immunodeficiency virus type 1 (HIV-1); however, their efficacy can be compromised by amyloid fibrils present in...
8.
Suarez I, Rauschning D, Schuller C, Hagemeier A, Stecher M, Lehmann C, et al.
Infection
. 2024 Mar;
52(4):1439-1448.
PMID: 38492196
Purpose: The risk of developing active tuberculosis (TB) is considerably increased in people living with HIV/AIDS (PLWH). However, incidence of HIV/TB coinfection is difficult to assess as surveillance data are...
9.
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
Pagani C, Rusconi C, Dalla Pria A, Ravano E, Schommers P, Bastos-Oreiro M, et al.
Blood Adv
. 2024 Jan;
8(4):968-977.
PMID: 38207206
Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone...
10.
Schommers P, Kim D, Schlotz M, Kreer C, Eggeling R, Hake A, et al.
Nat Med
. 2023 Nov;
29(11):2763-2774.
PMID: 37957379
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from...